12:00 AM
Feb 22, 2000
 |  BC Week In Review  |  Company News  |  Deals

Emisphere, Novartis deal

NOVN exercised its option to acquire exclusive worldwide development and commercialization rights from EMIS to oral salmon calcitonin...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >